Navigation Links
Anadys Pharmaceuticals Augments Management Team and Board of Directors
Date:1/6/2011

#160;

Dr. Appleman, who has been with Anadys since 2001 in positions of increasing responsibility, most recently as Senior Vice President, Research, played pivotal roles in the invention and characterization of the Company's drug development candidates ANA598 and ANA773.  Dr. Appleman will continue to be responsible for non-clinical aspects of both development programs.  Dr. Appleman was a faculty member at St. Jude Children's Research Hospital and subsequently held positions at Gensia, Inc. and Metabasis Therapeutics, Inc. prior to joining Anadys.  He received a Ph.D. in Biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

Dr. Freddo joined Anadys in 2006 as Chief Medical Officer to build out the Company's clinical and regulatory functions and was named Senior Vice President of Drug Development in 2008.  Under his leadership both ANA598 and ANA773 entered clinical development and advanced to their current status.   Dr. Freddo joined Anadys from Pfizer, Inc. where he was most recently Vice President, Clinical Site Head and Development Site Head, La Jolla, and led the team responsible for the registration of Sutent®.  Prior to Pfizer, Dr. Freddo held a number of drug development positions at Wyeth-Ayerst.  Dr. Freddo serves as a member of the Board of Directors for InfuSystems Holdings, Inc.  Dr. Freddo received his M.D. and completed his fellowship training at the University of North Carolina and served on the faculty of the UCSD Medical Center prior to joining industry.

Dr. Papadopoulos assumes the role of Chairman of the Board from Steven H. Holtzman, who has resigned from the Board of Directors in association with his recent appointment as Executive Vice President, Corporate Development at Biogen Idec Inc.  Dr. Papadopoulos, who is a co-founder of Anadys and has been a member of the Board since 2000, has more than 25 years experience
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
5. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
6. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
7. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
8. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
9. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
10. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... N.J., Nov. 10 Aton Pharma, Inc., ... a recent,survey of ophthalmologists regarding issues in ... dry eye. Aton provides the dry eye ... sustained release prescription insert that helps to ...
... - Seventh Study Showing Oncotype DX Frequently Changes Treatment ... Recommendations in Clinical Practice -, ... GHDX ) today announced the publication of results from ... way,physicians treat early-stage breast cancer. The study, published in the,October ...
... China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), ... and marketing biopharmaceutical products primarily in China,today announced ... Food and Drug,Administration (SFDA) for approval of NuLeusin ... carcinoma. If approved, NuLeusin is expected to,be the ...
Cached Biology Technology:Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 5Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the red flour beetle living happily in the flour sack ... University, and many others throughout the world, this pest of ... studying genetics. The superior status of this beetle, Tribolium ... work of two Kansas State University faculty, Susan Brown, professor ...
... League Baseball pitchers indicates that the height of the pitchers ... lead to potential injuries because of stress on the shoulder ... William Raasch, M.D., associate professor of orthopaedic surgery at the ... head team physician for the Milwaukee Brewers. Major League Baseball ...
... Mich. Michigan State University scientist Ned Walker is taking ... he believes he can help win the battle to save ... million grant from the National Science Foundation, Walker will lead ... the population dynamics of the parasite that causes the deadly ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Netting mosquitoes to prevent malaria 2
... microplate coating using advanced automated high throughput microplate processing equipment ... can also accommodate virtually any lot size of the following ... 8 and 12 well strips, ... 384 well microplate, ...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
A trigger solution for Flashlight labeled materials....
Biology Products: